

UCLA

UCLA Previously Published Works

Title

Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥ 18 Years - VISION and IVY Networks, September 2024-January 2025.

Permalink

<https://escholarship.org/uc/item/01w9h20q>

Journal

Morbidity and Mortality Weekly Report, 74(6)

Authors

Link-Gelles, Ruth
Chickery, Sean
Webber, Alexander
[et al.](#)

Publication Date

2025-02-27

DOI

10.15585/mmwr.mm7406a1

Peer reviewed

Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥ 18 Years — VISION and IVY Networks, September 2024–January 2025

Ruth Link-Gelles, PhD¹; Sean Chickery, DHSc²; Alexander Webber, MPH¹; Toan C. Ong, PhD³; Elizabeth A.K. Rowley, DrPH²; Malini B. DeSilva, MD⁴; Kristin Dascomb, MD, PhD⁵; Stephanie A. Irving, MHS⁶; Nicola P. Klein, MD, PhD⁷; Shaun J. Grannis, MD^{8,9}; Michelle A. Barron³; Sarah E. Reese, PhD²; Charlene McEvoy, MD⁴; Tamara Sheffield, MD⁵; Allison L. Naleway, PhD⁶; Ousseny Zerbo, PhD⁷; Colin Rogerson, MD^{9,10}; Wesley H. Self, MD¹¹; Yuwei Zhu, MD¹¹; Adam S. Luring, MD, PhD¹²; Emily T. Martin, PhD¹²; Ithan D. Peltan, MD^{13,14}; Adit A. Ginde, MD¹⁵; Nicholas M. Mohr, MD¹⁶; Kevin W. Gibbs, MD¹⁷; David N. Hager, MD, PhD¹⁸; Matthew E. Prekker, MD¹⁹; Amira Mohamed, MD²⁰; Nicholas Johnson, MD²¹; Jay S. Steingrub, MD²²; Akram Khan, MBBS²³; Jamie R. Felzer, MD²⁴; Abhijit Duggal, MD²⁵; Jennifer G. Wilson, MD²⁶; Nida Qadir, MD²⁷; Christopher Mallow, MD²⁸; Jennie H. Kwon, DO²⁹; Cristie Columbus, MD^{30,31}; Ivana A. Vaughn, PhD³²; Basmah Safdar, MD³³; Jarrod M. Mosier, MD³⁴; Estelle S. Harris, MD¹⁴; James D. Chappell, MD, PhD¹¹; Natasha Halasa, MD¹¹; Cassandra Johnson, MS¹; Karthik Natarajan, PhD^{35,36}; Nathaniel M. Lewis, PhD³⁷; Sascha Ellington, PhD³⁷; Emily L. Reeves, MPH³⁷; Jennifer DeCuir, MD, PhD³⁷; Meredith McMorro, MD¹; Clinton R. Paden, PhD¹; Amanda B. Payne, PhD¹; Fatimah S. Dawood, MD¹; Diya Surie, MD¹; CDC COVID-19 Vaccine Effectiveness Collaborators

Abstract

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023–24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥ 6 months receive a 2024–2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024–2025 COVID-19 vaccines was estimated against COVID-19–associated emergency department (ED) or urgent care (UC) visits during September 2024–January 2025 among adults aged ≥ 18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19–associated hospitalization in immunocompetent adults aged ≥ 65 years in two networks, and against COVID-19–associated hospitalization among adults aged ≥ 65 years with immunocompromising conditions in one network. Among adults aged ≥ 18 years, VE against COVID-19–associated ED/UC visits was 33% (95% CI = 28%–38%) during the first 7–119 days after vaccination. Among immunocompetent adults aged ≥ 65 years from two CDC networks, VE estimates against COVID-19–associated hospitalization were 45% (95% CI = 36%–53%) and 46% (95% CI = 26%–60%) during the first 7–119 days after vaccination. Among adults aged ≥ 65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%–54%) during the first 7–119 days after vaccination. These findings demonstrate that vaccination with

a 2024–2025 COVID-19 vaccine dose provides additional protection against COVID-19–associated ED/UC encounters and hospitalizations compared with not receiving a 2024–2025 dose and support current CDC and ACIP recommendations that all persons aged ≥ 6 months receive a 2024–2025 COVID-19 vaccine dose.

INSIDE

- 83 Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness — Four Vaccine Effectiveness Networks, United States, October 2024–February 2025
- 91 Reports of Encephalopathy Among Children with Influenza-Associated Mortality — United States, 2010–11 Through 2024–25 Influenza Seasons
- 96 Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022
- 102 Avian Influenza A(H5) Subtype in Wastewater — Oregon, September 15, 2021–July 11, 2024
- 107 QuickStats

Continuing Education examination available at https://www.cdc.gov/mmw/mmw_continuingEducation.html



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

Introduction

During September 24, 2023–August 11, 2024, approximately 800,000 COVID-19–associated hospitalizations occurred in the United States (1); adults aged ≥ 65 years accounted for 70% of these hospitalizations (2). During 2024, the SARS-CoV-2 Omicron JN.1 and JN.1-derived lineages predominated and were genomically divergent from the XBB lineages on which the 2023–2024 COVID-19 vaccines were based. On June 27, 2024, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended 2024–2025 COVID-19 vaccination with a Food and Drug Administration (FDA)–authorized or approved vaccine for all persons aged ≥ 6 months (3). In August 2024, FDA approved monovalent 2024–2025 COVID-19 vaccines by Moderna* and Pfizer-BioNTech† (based on the SARS-CoV-2 Omicron KP.2 lineage) and authorized a monovalent 2024–2025 COVID-19 vaccine by Novavax§ (based on the SARS-CoV-2 Omicron JN.1 lineage), for persons aged ≥ 12 years. For a majority of adults, 1 2024–2025 vaccine dose is recommended, although persons with moderate or severe immunocompromise and adults aged ≥ 65 years are recommended to receive additional doses, depending on their vaccination history and time since receipt of their most recent dose.¶

* <https://www.fda.gov/vaccines-blood-biologics/spikevax>

† <https://www.fda.gov/vaccines-blood-biologics/comirnaty>

§ <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted>

¶ <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

This analysis estimated 2024–2025 COVID-19 vaccine effectiveness (VE) against COVID-19–associated emergency department (ED) or urgent care (UC) visits in one CDC-funded VE network and VE against COVID-19–associated hospitalization in two CDC-funded VE networks during September 2024–January 2025** among adults aged ≥ 18 years.

Methods

Data Source

Methods for VE analyses in the Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION) and Investigating Respiratory Viruses in the Acutely Ill (IVY) network have been reported (4,5). VISION is a multisite, electronic health care records (EHR)–based network including 373 ED/UCs and 241 hospitals in eight states.†† Eligible patients are those who have received molecular (e.g., real-time reverse transcription–polymerase chain reaction [RT-PCR]) or antigen testing for SARS-CoV-2 during the 10 days preceding or ≤ 72 hours after an eligible ED/UC encounter or hospital

** The VISION analysis included ED/UC encounters and hospitalizations during September 1, 2024–January 21, 2025. The IVY network analysis included hospitalized patients admitted during September 1, 2024–January 30, 2025.

†† Sites from the CDC-funded VISION that contributed data for this analysis were HealthPartners (Minnesota and Wisconsin), Intermountain Health (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado).

The *MMWR* series of publications is published by the Office of Science, U.S. Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. *MMWR Morb Mortal Wkly Rep* 2025;74:[inclusive page numbers].

U.S. Centers for Disease Control and Prevention

Susan Monarez, PhD, *Acting Director*
Debra Houry, MD, MPH, *Chief Medical Officer and Deputy Director for Program and Science*
Samuel F. Posner, PhD, *Director, Office of Science*

MMWR Editorial and Production Staff (Weekly)

Michael Berkwits, MD, MSCE, *Editor in Chief*
Rachel Gorwitz, MD, MPH, *Acting Executive Editor*
Jacqueline Gindler, MD, *Editor*
Paul Z. Siegel, MD, MPH, *Associate Editor*
Mary Dott, MD, MPH, *Online Editor*
Terisa F. Rutledge, *Managing Editor*
Glenn Damon, *Acting Lead Technical Writer-Editor*
Stacy Simon, MA, Morgan Thompson,
Suzanne Webb, PhD, MA,
Technical Writer-Editors

Terraye M. Starr,
Acting Lead Health Communication Specialist
Alexander J. Gottardy, Maureen A. Leahy,
Stephen R. Spriggs, Armina Velarde, Tong Yang
Visual Information Specialists
Quang M. Doan, MBA,
Phyllis H. King, Moua Yang,
Information Technology Specialists

Kiana Cohen, MPH,
Leslie Hamlin, Lowery Johnson,
Health Communication Specialists
Will Yang, MA,
Visual Information Specialist

MMWR Editorial Board

Matthew L. Boulton, MD, MPH
Carolyn Brooks, ScD, MA
Virginia A. Caine, MD
Jonathan E. Fielding, MD, MPH, MBA

Timothy F. Jones, MD, *Chairman*
David W. Fleming, MD
William E. Halperin, MD, DrPH, MPH
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH

Patrick L. Remington, MD, MPH
Carlos Roig, MS, MA
William Schaffner, MD
Morgan Bobb Swanson, MD, PhD

admission.^{§§} COVID-19 vaccination history is ascertained from state or jurisdictional registries, EHRs and, in a subset of sites, medical claims data.^{¶¶}

IVY is a multicenter, inpatient network of 26 hospitals in 20 U.S. states^{***} and prospectively enrolls adults aged ≥18 years with COVID-19–like illness^{†††} who receive molecular or antigen testing for SARS-CoV-2 within 10 days of illness onset and

within 3 days of hospital admission. Nasal swabs are collected at enrollment for central RT-PCR testing for SARS-CoV-2 at Vanderbilt University Medical Center (Nashville, Tennessee); SARS-CoV-2–positive specimens are sent to the University of Michigan (Ann Arbor, Michigan) for whole genome sequencing to identify SARS-CoV-2 lineages. Demographic and clinical data are collected through EHR review and patient or proxy interview. COVID-19 vaccination history is ascertained from state or jurisdictional registries, EHRs, and plausible self-report based on known location and dates of vaccination.

In both analyses, persons who had received the 2024–2025 COVID-19 vaccine ≥7 days before the encounter index date (VISION) or illness onset date (IVY) were considered vaccinated. Those who had not received the 2024–2025 COVID-19 vaccine (regardless of previous COVID-19 vaccination or infection history) were considered not vaccinated and served as comparators.

Data Analysis

The VISION and IVY networks conducted separate VE analyses using test-negative designs (4,5). In both analyses, adults aged ≥18 years with COVID-19–like illness who 1) had a medical encounter at an ED/UC (VISION only) or 2) were hospitalized (VISION and IVY) at a participating facility were included. Case-patients were those who received a positive SARS-CoV-2 molecular or antigen test result, and control patients were those who received a negative SARS-CoV-2 molecular test result. Participants were excluded if they 1) had received a 2024–2025 COVID-19 vaccine <7 days or ≥120 days before their eligible ED/UC encounter or hospitalization, 2) had received a 2024–2025 COVID-19 vaccine dose <2 months after receiving a previous COVID-19 vaccine dose, or 3) were immunocompetent persons who had received more than 1 2024–2025 COVID-19 vaccine dose. COVID-19 case-patients were also excluded if they were co-infected with influenza or respiratory syncytial virus (RSV) at the time of their COVID-19–like illness encounter. Because of potential confounding from correlated vaccination behaviors, control patients with a positive or indeterminant influenza test result (adults ≥18 years) or a positive RSV test result (adults ≥60 years) were excluded from the primary analysis (6,7). Previous SARS-CoV-2 infections are incompletely documented in medical records; therefore, patients were included regardless of prior SARS-CoV-2 infections.

Odds ratios (OR) and 95% CIs were estimated using multivariable logistic regression, comparing persons who received a 2024–2025 COVID-19 vaccine dose with those who did not among case- and control patients, regardless of previous COVID-19 vaccination. VE models were adjusted a priori for age, sex, race and ethnicity, calendar time, and geographic

^{§§} Eligible ED/UC encounters or hospital admissions were those for COVID-19–like illness, obtained using *International Classification of Diseases, Tenth Revision* (ICD-10) discharge codes. The specific codes used were COVID-19 pneumonia: J12.81 and J12.82; influenza pneumonia: J09.X1, J10.0*, J11.0*, and other viral pneumonia: J12*; bacterial and other pneumonia: J13, J14, J15*, J16*, J17, and J18*; influenza disease: J09*, J10.1, J10.2, J10.8*, J11.1, J11.2, and J11.8*; acute respiratory distress syndrome: J80; chronic obstructive pulmonary disease with acute exacerbation: J44.1; acute asthma exacerbation: J45.21, J45.22, J45.31, J45.32, J45.41, J45.42, J45.51, J45.52, J45.901, and J45.902; respiratory failure: J96.0*, J96.2*, R09.2, and J96.9*; other acute lower respiratory tract infections: B97.4, J20*, J21*, J22, J40, J44.0, J41*, J42, J43*, J47*, J85*, and J86*; acute and chronic sinusitis: J01* and J32*; acute upper respiratory tract infections: J00*, J02*, J03*, J04*, J05*, and J06*; acute respiratory illness signs and symptoms: R04.2, R05, R05.1, R05.2, R05.4, R05.8, R05.9, R06.00, R06.02, R06.03, R06.1, R06.2, R06.8, R06.81, R06.82, R06.89, R07.1, R09.0*, R09.1, R09.2, R09.3, and R09.8*; acute febrile illness signs and symptoms: R50*, R50.81, R50.9, and R68.83; acute nonrespiratory illness signs and symptoms: M79.10, M79.18, R10.0, R10.1*, R10.2, R10.3*, R10.81*, R10.84, R10.9, R11.0, R11.10, R11.11, R11.15, R11.2, R19.7, R21*, R40.0, R40.1, R41.82, R43*, R51.9, R53.1, R53.81, R53.83, R57.9, and R65*; febrile convulsions: R56.0; viral and respiratory diseases complicating pregnancy, childbirth, and puerperium: O98.5*, O98.8*, O98.9*, O99.5*. All ICD-10 codes with * include all child codes under the specific parent code.

^{¶¶} National pharmacy chains were required to establish bidirectional linkage with jurisdictional immunization information systems (IISs) to support vaccine distribution early in the COVID-19 pandemic; thus, doses administered at pharmacies should be reported to IISs.

^{***} Sites from the CDC-funded IVY network that contributed data for this analysis were Barnes-Jewish Hospital (St. Louis, Missouri), Baylor Scott & White Medical Center (Temple, Texas), Baylor University Medical Center (Dallas, Texas), Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Cleveland Clinic (Cleveland, Ohio), Emory University Medical Center (Atlanta, Georgia), Hennepin County Medical Center (Minneapolis, Minnesota), Henry Ford Health (Detroit, Michigan), Intermountain Medical Center (Murray, Utah), Johns Hopkins Hospital (Baltimore, Maryland), Montefiore Medical Center (New York, New York), Oregon Health and Science University Hospital (Portland, Oregon), Ronald Reagan UCLA Medical Center (Los Angeles, California), Stanford University Medical Center (Stanford, California), The Ohio State University Wexner Medical Center (Columbus, Ohio), UHealth University of Colorado Hospital (Aurora, Colorado), University of Arizona Medical Center (Tucson, Arizona), University of Iowa Hospitals (Iowa City, Iowa), University of Miami Medical Center (Miami, Florida), University of Michigan Hospital (Ann Arbor, Michigan), University of Utah (Salt Lake City, Utah), University of Washington (Seattle, Washington), Vanderbilt University Medical Center (Nashville, Tennessee), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), and Yale University (New Haven, Connecticut).

^{†††} In the IVY network analysis, COVID-19–like illness was defined as one or more of the following signs and symptoms: fever, cough, dyspnea, new or worsening findings on chest imaging consistent with pneumonia, or hypoxemia defined as SpO₂ <92% on room air or supplemental oxygen to maintain SpO₂ ≥92%. For patients on chronic oxygen therapy, hypoxemia was defined as SpO₂ below baseline or an escalation of supplemental oxygen to maintain a baseline SpO₂.

region.^{§§§} VE was calculated as $(1 - \text{adjusted OR}) \times 100\%$ during the first 7–119 days since receipt of a 2024–2025 COVID-19 vaccine dose and separately during the first 7–59 days and 60–119 days since receipt of a dose. For ED/UC encounters, VE was estimated for persons aged ≥ 18 years, 18–64 years, and ≥ 65 years (Supplementary Table 1, <https://stacks.cdc.gov/view/cdc/176586>). Statistical power to estimate VE against hospitalization was limited in adults aged 18–64 years; therefore, VE against hospitalization was only estimated for adults aged ≥ 65 years in both networks. In the IVY network, VE against hospitalization was estimated in immunocompetent adults due to limited statistical power to assess VE for immunocompromised adults; in VISION, VE was estimated for all adults in the ED/UC setting and separately for adults with and without immunocompromising conditions in the hospital setting.^{¶¶¶} The distribution of case- and control patients aged 5–17 years was explored in VISION; however, statistical power was limited in both the ED/UC and hospital settings, so frequencies are described without VE estimation (Supplementary Table 2; <https://stacks.cdc.gov/view/cdc/176592>).

Analyses were conducted using R software (version 4.3.2; R Foundation) for the VISION analysis and R software (version 4.4.0; R Foundation) for the IVY network analysis. This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.^{****}

^{§§§} VISION regression models were adjusted for age, sex, race and ethnicity, calendar day, and geographic region with age and calendar day included as natural cubic splines. Geographic region was included in the model based on site-defined geographic cluster of the final discharge facility of the encounter. IVY network regression models were adjusted for age, sex, race and ethnicity, calendar time in biweekly intervals, and U.S. Department of Health and Human Services region.

^{¶¶¶} Immunocompromising conditions were obtained from ICD-10 discharge codes. The specific codes used were hematologic malignancy: C81.*, C82.*, C83.*, C84.*, C85.*, C86.*, C88.*, C90.*, C91.*, C92.*, C93.*, C94.*, C95.*, C96.*, D46.*, D61.0*, D70.0, D61.2, D61.9, and D71.*; solid malignancy: C00.*, C01.*, C02.*, C03.*, C04.*, C05.*, C06.*, C07.*, C08.*, C09.*, C10.*, C11.*, C12.*, C13.*, C14.*, C15.*, C16.*, C17.*, C18.*, C19.*, C20.*, C21.*, C22.*, C23.*, C24.*, C25.*, C26.*, C30.*, C31.*, C32.*, C33, C34.*, C37, C38.*, C39.*, C40.*, C41.*, C43.*, C45.*, C46.*, C47.*, C48.*, C49.*, C50.*, C51.*, C52, C53.*, C54.*, C55, C56.*, C57.*, C58, C60.*, C61, C62.*, C63.*, C64.*, C65.*, C66.*, C67.*, C68.*, C69.*, C70.*, C71.*, C72.*, C73, C74.*, C75.*, C76.*, C77.*, C78.*, C79.*, C7A.*, C7B.*, C80.*, Z51.0, Z51.1*, and C4A.*; transplant: T86.0*, T86.1*, T86.2*, T86.3*, T86.4*, T86.5*, T86.81*, T86.85*, D47.Z1, Z48.2*, and Z94.*, and Z98.85; rheumatologic/inflammatory disorders: D86.*, E85.1, E85.2, E85.3, E85.4, E85.8*, E85.9, G35, J67.9, L40.54, L40.59, L93.0, L93.2, L94.*, M05.*, M06.*, M07.*, M08.*, M30.*, M31.3*, M31.5, M32.*, M33.*, M34.*, M35.3, M35.89, M35.9, M46.0*, M46.1, M46.8*, and M46.9*; other intrinsic immune condition or immunodeficiency: D27.9, D72.89, D80.*, D81.0, D81.1, D81.2, D81.4, D81.5, D81.6, D81.7, D81.8*, D81.9, D82.*, D83.*, D84.*, D89.0, D89.1, D89.3, D89.4*, D89.8*, D89.9, K70.3*, K70.4*, K72.*, K74.3, K74.4, K74.5, K74.6*, N04.*, and R18.0; HIV: B20.*, B21.*, B22.*, B23.*, B97.35, O98.7*, and Z21. All ICD-10 codes with * include all child codes under the specific parent code.

^{****} 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

Results

2024–2025 COVID-19 VE Against COVID-19–associated ED/UC Visits, VISION

Among adults aged ≥ 18 years in VISION, 137,543 ED/UC encounters met criteria for inclusion in the analyses, including 10,459 (8%) case-patients and 127,084 (92%) control patients (Table 1). Effectiveness of a 2024–2025 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% CI = 28%–38%) during the first 7–119 days after vaccination, 36% (95% CI = 29%–42%) during the first 7–59 days after vaccination, and 30% (95% CI = 22%–37%) during the 60–119 days after vaccination (Table 2).

2024–2025 COVID-19 VE Against COVID-19–associated Hospitalization, VISION and IVY Networks Among Older Adults

Among adults aged ≥ 65 years without immunocompromising conditions in VISION, 26,219 hospitalizations met criteria for inclusion in analyses, including 2,248 (9%) case-patients and 23,971 (91%) control patients. VE of a 2024–2025 COVID-19 vaccine dose against COVID-19–associated hospitalization was 45% (95% CI = 36%–53%) a median interval of 53 days since receipt of a 2024–2025 COVID-19 vaccine dose (Table 3). Among adults aged ≥ 65 years with immunocompromising conditions in VISION, 8,192 hospitalizations met criteria for inclusion in analyses, including 598 (7%) case-patients and 7,594 (93%) control patients. VE was 40% (95% CI = 21%–54%), a median interval of 53 days after receipt of a 2024–2025 COVID-19 vaccination. Among adults aged ≥ 65 years without immunocompromising conditions in the IVY network, 1,929 met inclusion criteria, including 683 (35%) case-patients and 1,246 (65%) control patients. VE against COVID-19–associated hospitalization was 46% (95% CI = 26%–60%), a median of 60 days after receipt of a 2024–2025 COVID-19 vaccine dose.

Whole Genome Sequencing of SARS-CoV-2 Specimens, IVY Network

Among adults aged ≥ 18 years in the IVY network, 653 SARS-CoV-2–positive specimens collected during September 1, 2024–December 31, 2024 were successfully sequenced; 55 (8.4%) had JN.1-like spike proteins, 92 (14.1%) had KP.2-like proteins, 340 (52.1%) had KP.3-like proteins, 126 (19.3%) had XEC-like proteins, and 40 (6.1%) had other spike proteins.^{††††} Similarly,

^{††††} SARS-CoV-2 lineages during the period of this analysis were classified according to their clade assignment as follows: sequences with clades 24A and 23I were grouped together as JN.1-like lineages; clades 24G and 24B were grouped together as KP.2-like lineages; clades 24C and 24E were grouped together as KP.3-like lineages; clade 24F represented XEC lineage; and “Other” represents non-JN.1-derived or recombinant viruses detected during September 1–December 31, 2024.

TABLE 1. Characteristics of emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years with COVID-19–like illness, by COVID-19 case status and CDC vaccine effectiveness network — VISION and IVY Networks,* September 2024–January 2025

Characteristic	VE network and setting, no. (column %)								
	VISION ED/UC encounters, all adults aged ≥18 years			VISION hospitalizations, all adults aged ≥65 years			IVY hospitalizations, immunocompetent adults aged ≥65 years		
	Total	COVID-19 case-patients	COVID-19 control patients	Total	COVID-19 case-patients	COVID-19 control patients	Total	COVID-19 case-patients	COVID-19 control patients
All encounters	137,543	10,459	127,084	34,411	2,846	31,565	1,929	683	1,246
2024–2025 COVID-19 vaccination status									
No 2024–2025 dose [†]	118,517 (86)	9,545 (91)	108,972 (86)	27,623 (80)	2,540 (89)	25,083 (79)	1,635 (85)	614 (90)	1,021 (82)
Received 2024–2025 dose									
7–119 days earlier	19,026 (14)	914 (9)	18,112 (14)	6,788 (20)	306 (11)	6,482 (21)	294 (15)	69 (10)	225 (18)
7–59 days earlier	10,269 (7)	480 (5)	9,789 (8)	3,904 (11)	179 (6)	3,725 (12)	146 (8)	41 (6)	105 (8)
60–119 days earlier	8,757 (6)	434 (4)	8,323 (7)	2,884 (8)	127 (4)	2,757 (9)	148 (8)	28 (4)	120 (10)
Median age, yrs (IQR)	53 (34–72)	58 (37–74)	53 (34–71)	78 (72–84)	79 (73–86)	78 (71–84)	77 (71–84)	78 (72, 85)	76 (70, 83)
Age group, yrs[§]									
18–64	88,858 (65)	6,113 (58)	82,745 (65)	—	—	—	—	—	—
≥65	48,685 (35)	4,346 (42)	44,339 (35)	34,411 (100)	2,846 (100)	31,565 (100)	1,929 (100)	683 (100)	1,246 (100)
Female sex	83,641 (61)	6,275 (60)	77,366 (61)	18,274 (53)	1,412 (50)	16,862 (53)	1,050 (54)	374 (55)	676 (54)
Race and ethnicity									
Black or African American, NH	15,003 (11)	794 (8)	14,209 (11)	2,575 (7)	156 (5)	2,419 (8)	370 (19)	120 (18)	250 (20)
White, NH	83,282 (61)	7,256 (69)	76,026 (60)	25,811 (75)	2,281 (80)	23,530 (75)	1,223 (63)	447 (65)	776 (62)
Hispanic or Latino, any race	20,461 (15)	1,255 (12)	19,206 (15)	2,640 (8)	183 (6)	2,457 (8)	184 (10)	59 (9)	125 (10)
Other, NH [¶]	14,014 (10)	897 (9)	13,117 (10)	2,858 (8)	188 (7)	2,670 (8)	89 (5)	34 (5)	55 (4)
Unknown**	4,783 (3)	257 (2)	4,526 (4)	527 (2)	38 (1)	489 (2)	63 (3)	23 (3)	40 (3)
HHS region^{††}									
1	0	0	0	0	0	0	614 (32)	235 (34)	379 (30)
2	0	0	0	0	0	0	104 (5)	23 (3)	81 (7)
3	0	0	0	0	0	0	21 (1)	10 (2)	11 (1)
4	0	0	0	0	0	0	279 (15)	93 (14)	186 (15)
5	45,211 (33)	3,416 (33)	41,795 (33)	13,844 (40)	1,261 (44)	12,583 (40)	248 (13)	115 (17)	133 (11)
6	0	0	0	0	0	0	144 (8)	33 (5)	111 (9)
7	0	0	0	0	0	0	52 (3)	11 (2)	41 (3)
8	33,345 (24)	4,519 (43)	28,826 (23)	6,217 (18)	696 (24)	5,521 (17)	254 (13)	86 (13)	168 (14)
9	48,738 (35)	1,728 (17)	47,010 (37)	12,574 (37)	766 (27)	11,808 (37)	154 (8)	54 (8)	100 (8)
10	10,249 (7)	796 (8)	9,453 (7)	1,776 (5)	123 (4)	1,653 (5)	59 (3)	23 (3)	36 (3)
No. of organ systems with a chronic medical condition, median (IQR)^{§§}	0 (0–1)	0 (0–1)	0 (0–1)	3 (2–4)	3 (2–4)	3 (2–4)	3 (2, 4)	2 (2, 3)	3 (2, 4)
Immunocompromised^{¶¶}	—	—	—	8,192 (24)	598 (21)	7,594 (24)	—	—	—
Month/Yr. of COVID-19–associated ED/UC encounter or hospitalization									
Sep 2024	28,086 (20)	3,675 (35)	24,411 (19)	7,723 (22)	982 (35)	6,741 (21)	508 (26)	229 (34)	279 (22)
Oct 2024	28,364 (21)	1,927 (18)	26,437 (21)	7,641 (22)	557 (20)	7,084 (22)	377 (20)	147 (22)	230 (19)
Nov 2024	28,040 (20)	1,465 (14)	26,575 (21)	7,751 (23)	408 (14)	7,343 (23)	312 (16)	114 (17)	198 (16)
Dec 2024	38,148 (28)	2,712 (26)	35,436 (28)	9,063 (26)	771 (27)	8,292 (26)	394 (20)	125 (18)	269 (22)
Jan 2025	14,905 (11)	680 (7)	14,225 (11)	2,233 (6)	128 (4)	2,105 (7)	338 (18)	68 (10)	270 (22)

Abbreviations: ED = emergency department; EHR = electronic health care records; HHS = U.S. Department of Health and Human Services; IVY = Investigating Respiratory Viruses in the Acutely Ill; NH = non-Hispanic; UC = urgent care; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network. * Sites from the CDC-funded VISION that contributed data for this analysis were HealthPartners (Minnesota and Wisconsin), Intermountain Health (Utah), Kaiser Permanente Northern California (California), Kaiser Permanente Northwest (Oregon and Washington), Regenstrief Institute (Indiana), and University of Colorado (Colorado). Sites from the CDC-funded IVY network that contributed data for this analysis were Barnes-Jewish Hospital (St. Louis, Missouri), Baylor Scott & White Medical Center (Temple, Texas), Baylor University Medical Center (Dallas, Texas), Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Cleveland Clinic (Cleveland, Ohio), Emory University Medical Center (Atlanta, Georgia), Hennepin County Medical Center (Minneapolis, Minnesota), Henry Ford Health (Detroit, Michigan), Intermountain Medical Center (Murray, Utah), Johns Hopkins Hospital (Baltimore, Maryland), Montefiore Medical Center (New York, New York), Oregon Health and Science University Hospital (Portland, Oregon), Ronald Reagan UCLA Medical Center (Los Angeles, California), Stanford University Medical Center (Stanford, California), The Ohio State University Wexner Medical Center (Columbus, Ohio), UHealth University of Colorado Hospital (Aurora, Colorado), University of Arizona Medical Center (Tucson, Arizona), University of Iowa Hospitals (Iowa City, Iowa), University of Miami Medical Center (Miami, Florida), University of Michigan Hospital (Ann Arbor, Michigan), University of Utah (Salt Lake City, Utah), University of Washington (Seattle, Washington), Vanderbilt University Medical Center (Nashville, Tennessee), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), and Yale University (New Haven, Connecticut).

[†] The “no 2024–2025 dose” group included all eligible persons who did not receive 2024–2025 COVID-19 vaccine dose, regardless of number of previous doses (if any) received. See table footnotes continued on the next page.

TABLE 1. (Continued) Characteristics of emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years with COVID-19–like illness, by COVID-19 case status and CDC vaccine effectiveness network — VISION and IVY Networks,* September 2024–January 2025

[§] In VISION, a total of 18,289 eligible hospitalizations were reported in adults aged 18–64 years, including 804 (4%) case-patients and 17,485 (96%) control patients. Of the hospitalized case-patients, 35 (4%) had received a 2024–2025 COVID-19 vaccine. Of the hospitalized control patients, 1,277 (7%) had received a 2024–2025 COVID-19 vaccine. In IVY, a total of 1,446 eligible hospitalizations were reported in adults aged 18–64 years, including 342 (24%) case-patients and 1,104 (76%) control patients. Of the case-patients aged 18–64 years, 16 (5%) had received a 2024–2025 COVID-19 vaccine. Of the control patients aged 18–64 years, 69 (6%) had received a 2024–2025 COVID-19 vaccine.

[¶] For VISION, “Other, non-Hispanic” race includes persons reporting non-Hispanic ethnicity and any of the following for race: American Indian or Alaska Native, Asian, Native Hawaiian or Pacific Islander, Middle Eastern or North African, other races not listed, and multiple races. Because of small numbers, these categories were combined. For IVY, “Other race, non-Hispanic” includes Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander and patients who self-reported their race and ethnicity as, “Other”; these groups were combined because of small counts.

^{**} For VISION, “Unknown” includes persons with missing race and ethnicity in their EHR. For IVY, “Unknown” refers to patients who did not report their race and ethnicity.

^{††} In VISION, geographic region was included in the model based on site-defined geographic cluster of the final discharge facility of the encounter. In IVY, geographic region was included in the model based on HHS region. HHS regions are included to illustrate geographic spread across both networks. Regions are defined by HHS. States included in each region are available at <https://www.hhs.gov/about/agencies/iea/regional-offices/index.html>. VISION sites included were located as follows: *Region 5*: HealthPartners (Minnesota and Wisconsin) and Regenstrief Institute (Indiana); *Region 8*: Intermountain Healthcare (Utah) and University of Colorado (Colorado); *Region 9*: Kaiser Permanente Northern California (California); and *Region 10*: Kaiser Permanente Northwest (Oregon and Washington). IVY network sites were located as follows: *Region 1*: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), and Yale University (New Haven, Connecticut); *Region 2*: Montefiore Medical Center (New York, New York); *Region 3*: Johns Hopkins Hospital (Baltimore, Maryland); *Region 4*: Emory University Medical Center (Atlanta, Georgia), University of Miami Medical Center (Miami, Florida), Vanderbilt University Medical Center (Nashville, Tennessee), and Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina); *Region 5*: Cleveland Clinic (Cleveland, Ohio), Hennepin County Medical Center (Minneapolis, Minnesota), Henry Ford Health (Detroit, Michigan), The Ohio State University Wexner Medical Center (Columbus, Ohio), and University of Michigan Hospital (Ann Arbor, Michigan); *Region 6*: Baylor Scott & White Medical Center (Temple, Texas) and Baylor University Medical Center (Dallas, Texas); *Region 7*: Barnes-Jewish Hospital (St. Louis, Missouri) and University of Iowa Hospitals (Iowa City, Iowa); *Region 8*: Intermountain Medical Center (Murray, Utah), UCHHealth University of Colorado Hospital (Aurora, Colorado), and University of Utah (Salt Lake City, Utah); *Region 9*: Stanford University Medical Center (Stanford, California), Ronald Reagan UCLA Medical Center (Los Angeles, California), and University of Arizona Medical Center (Tucson, Arizona); and *Region 10*: Oregon Health and Science University Hospital (Portland, Oregon) and University of Washington (Seattle, Washington).

^{§§} VISION underlying medical condition categories included pulmonary, cardiovascular, cerebrovascular, neurologic or musculoskeletal, hematologic, endocrine, renal, and gastrointestinal. IVY network underlying medical condition categories included pulmonary, cardiovascular, neurologic, hematologic, endocrine, kidney, gastrointestinal, and autoimmune.

^{¶¶} Immunocompromised status is not evaluated for ED/UC encounters because of a higher likelihood of incomplete discharge diagnosis codes in this setting. In IVY, a total of 656 eligible hospitalizations were reported in adults aged ≥65 years with immunocompromise, including 178 (27%) case-patients and 478 (73%) control patients. Of the case-patients aged ≥65 years with immunocompromise, 24 (13%) had received a 2024–2025 COVID-19 vaccine. Of the control patients aged ≥65 years with immunocompromise, 102 (21%) had received a 2024–2025 COVID-19 vaccine. Immunocompromised adults were excluded from the IVY Network’s VE analyses due to limited sample size.

among 6,491 SARS-CoV-2–positive specimens collected during the same period and sequenced by CDC as part of national genomic surveillance,^{§§§§} 928 (14.3%) had JN.1-like spike proteins, 982 (15.1%) had KP.2-like proteins, 3,430 (52.8%) had KP.3-like proteins, 894 (13.8%) XEC-like proteins, and 257 (4.0%) had other spike proteins.

Discussion

During September 2024–January 2025, 2024–2025 COVID-19 vaccination provided additional protection against COVID-19–associated ED/UC encounters and hospitalizations among adults with and without immunocompromising conditions, compared with not receiving a 2024–2025 COVID-19 vaccine dose. These results support current CDC recommendations for 2024–2025 COVID-19 vaccination, irrespective of previous COVID-19 vaccination and infection history, and represent the added benefit of 2024–2025 COVID-19 vaccination above existing protection from previous vaccination or infection (3).

During the analytic period, the primary circulating SARS-CoV-2 lineages were descendants of the Omicron

JN.1 lineage, including KP.2, KP.3, and XEC.^{¶¶¶¶} XEC is closely related to the KP.2 and JN.1 strains in the 2024–2025 COVID-19 vaccines, which might account for the sustained protection from COVID-19 vaccination observed during the analysis period, despite the emergence and increasing prevalence of XEC. Starting in January 2025, prevalence of LP.8.1 (a JN.1 and KP.1.1 descendent) began to increase, accounting for 31% of sequences in CDC’s national genomic surveillance as of February 15, 2025. The pace and frequency with which new SARS-CoV-2 lineages have become predominant underscores the need for ongoing monitoring of COVID-19 VE and genomic surveillance.

COVID-19–associated hospitalization rates during the time frame of this analysis were relatively low compared with those during previous years, precluding estimation of VE against critical illness (i.e., intensive care unit admission, invasive mechanical ventilation, or death); VE against these outcomes has historically been higher and more sustained than that against less severe outcomes (4,5,8). Because of both lower hospitalization rates and lower vaccination rates,^{*****} VE could not be estimated for children and adolescents aged

^{§§§§} CDC national SARS-CoV-2 genomic surveillance includes samples sequenced by CDC and national testing laboratories contracted by CDC.

^{¶¶¶¶} <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>
^{*****} <https://www.cdc.gov/respxview/about>

TABLE 2. Effectiveness of 2024–2025 COVID-19 vaccination against COVID-19–associated emergency department or urgent care encounters, by age group — VISION, September 2024–January 2025

Age group/COVID-19 vaccination dosage pattern	COVID-19 case patients No. (col %)	COVID-19 control patients No. (col %)	Median interval since last dose for vaccinated, days (IQR)	VE %* (95% CI)
≥18 yrs				
No 2024–2025 dose [†] (Ref)	9,545 (91)	108,972 (86)	998 (539–1,142)	Ref
Received 2024–2025 dose				
7–119 days earlier	914 (9)	18,112 (14)	55 (32–80)	33 (28–38)
7–59 days earlier	480 (5)	9,789 (8)	33 (20–46)	36 (29–42)
60–119 days earlier	434 (4)	8,323 (7)	82 (71–97)	30 (22–37)
18–64 yrs				
No 2024–2025 dose [†] (Ref)	5,860 (96)	76,792 (93)	1,042 (751–1,180)	Ref
Received 2024–2025 dose				
7–119 days earlier	253 (4)	5,953 (7)	53 (29–77)	30 (20–39)
7–59 days earlier	134 (2)	3,379 (4)	32 (20–45)	36 (23–46)
60–119 days earlier	119 (2)	2,574 (3)	81 (70–95)	21 (5–35)
≥65 yrs				
No 2024–2025 dose [†] (Ref)	3,685 (85)	32,180 (73)	750 (346–1,076)	Ref
Received 2024–2025 dose				
7–119 days earlier	661 (15)	12,159 (27)	57 (33–82)	35 (29–41)
7–59 days earlier	346 (8)	6,410 (14)	34 (21–47)	36 (28–44)
60–119 days earlier	315 (7)	5,749 (13)	83 (71–97)	34 (25–42)

Abbreviations: Ref = referent group; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network.

* VE was calculated by comparing the odds of 2024–2025 COVID-19 vaccination among case-patients and control patients using the following equation: (1 – adjusted odds ratio) x 100%. Odds ratios were estimated by multivariable logistic regression. The odds ratio was adjusted for age, sex, race and ethnicity, calendar day, and geographic region.

[†] The “no 2024–2025 dose” group included all eligible persons who did not receive a 2024–2025 COVID-19 vaccine dose, regardless of number of previous COVID-19 vaccine doses (if any) received.

5–17 years for either outcome or for adults aged 18–64 years against hospitalization. Analyses from previous years have indicated that COVID-19 vaccines provide similar protection across age groups. For the 2023–2024 COVID-19 vaccines, VE against ED/UC encounters during the first 60–179 days after vaccination was 24% (95% CI = -31% to 56%) for children aged 9 months–4 years, 50% (95% CI = 22%–68%) for children and adolescents aged 5 years–17 years, 24% (95% CI = 17%–31%) for adults aged 18–64 years, and 25% (95% CI = 20%–30%) for adults aged ≥65 years.^{††††}

Previous SARS-CoV-2 infection contributes protection against future disease, although protection wanes over time (9). An increase in SARS-CoV-2 circulation in the United States during late summer 2024, just before the 2024–2025 COVID-19 vaccines were approved and authorized, might have resulted in higher population-level immunity against JN.1-lineage strains, which could have resulted in lower

^{††††} <https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/03-COVID-Link-Gelles-508.pdf>

TABLE 3. Effectiveness of 2024–2025 COVID-19 vaccination against COVID-19–associated hospitalization among adults aged ≥65 years — VISION and IVY Networks, September 2024–January 2025

VE network/ Immunocompromise status/ COVID-19 vaccination dosage pattern	COVID-19 case-patients No. (col %)	COVID-19 control patients No. (col %)	Median interval since last dose for vaccinated, days (IQR)	VE %* (95% CI)
VISION, immunocompetent				
No 2024–2025 dose [†] (Ref)	2,016 (90)	19,198 (80)	775 (357–1,084)	Ref
Received 2024–2025 dose				
7–119 days earlier	232 (10)	4,773 (20)	53 (30–77)	45 (36–53)
7–59 days earlier	129 (6)	2,759 (12)	33 (20–46)	42 (30–52)
60–119 days earlier	103 (5)	2,014 (8)	81 (70–94)	48 (36–58)
VISION, immunocompromised				
No 2024–2025 dose [†] (Ref)	524 (88)	5,885 (78)	720 (343–1,064)	Ref
Received 2024–2025 dose				
7–119 days earlier	74 (12)	1,709 (22)	53 (31–78)	40 (21–54)
IVY network, immunocompetent				
No 2024–2025 dose [†] (Ref)	614 (90)	1,021 (82)	— [§]	Ref
Received 2024–2025 dose				
7–119 days earlier	69 (10)	225 (18)	60 (31–85)	46 (26–60)
7–59 days earlier	41 (6)	105 (9)	31 (20–45)	42 (14–61)
60–119 days earlier	28 (4)	120 (10)	85 (72–98)	47 (17–67)

Abbreviations: Ref = referent group; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network; IVY = Investigating Respiratory Viruses in the Acutely Ill.

* VE was calculated by comparing the odds of 2024–2025 COVID-19 vaccination in case-patients and control patients using the equation: (1 – adjusted odds ratio) x 100%. Odds ratios were estimated by multivariable logistic regression. For VISION, the odds ratio was adjusted for age, sex, race and ethnicity, calendar day, and geographic region. For IVY, the odds ratio was adjusted for age, sex, race and ethnicity, geographic region (U.S. Department of Health and Human Services region), and calendar time (biweekly intervals).

[†] The “no 2024–2025 dose” group included all eligible persons who did not receive a 2024–2025 COVID-19 vaccine dose, regardless of number of previous COVID-19 vaccine doses (if any) received.

[§] Median interval from last dose for persons who received previous doses of COVID-19 vaccine but did not receive a 2024–2025 COVID-19 vaccine dose was not available in the IVY network.

measured VE than would have been detected in a population with less recent infection. Analyses did not account for previous SARS-CoV-2 infection or previous COVID-19 vaccination (e.g., original monovalent, bivalent, or 2023–2024 doses). VE should therefore be interpreted as the added benefit of 2024–2025 COVID-19 vaccination in a population with high levels of infection-induced immunity, vaccine-induced immunity, or both.

Limitations

The findings in this report are subject to at least four limitations. First, although case-patients were those who met a COVID-19–like illness definition and had a positive SARS-CoV-2 test result, they might have visited ED/UCs or been hospitalized for reasons other than COVID-19, which might have lowered VE estimates. Second, misclassification

Summary**What is already known about this topic?**

In June 2024, CDC's Advisory Committee on Immunization Practices (ACIP) recommended 2024–2025 COVID-19 vaccination for all persons aged ≥ 6 months to provide additional protection against severe COVID-19.

What is added by this report?

Vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults aged ≥ 18 years and 45%–46% against hospitalizations among immunocompetent adults aged ≥ 65 years, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults aged ≥ 65 years was 40%.

What are the implications for public health practice?

These findings indicate that 2024–2025 COVID-19 vaccination provides additional protection against COVID-19–associated ED/UC encounters and hospitalization, versus no 2024–2025 vaccination and support CDC and ACIP recommendations that all persons aged ≥ 6 months receive 2024–2025 COVID-19 vaccination.

of vaccination status was possible, which would likely result in underestimation of VE if the misclassification was nondifferential. Third, lack of statistical power prevented estimation of VE in some strata, including younger age groups. Finally, although analyses were adjusted for some relevant confounders, residual confounding from other factors, such as behavioral modifications to prevent SARS-CoV-2 exposure and outpatient antiviral treatment for COVID-19, might remain.

Implications for Public Health Practice

In this analysis, receipt of a 2024–2025 COVID-19 vaccine dose provided additional protection against COVID-19–associated ED/UC visits and hospitalization among adults with and without immunocompromise. These results support CDC and ACIP recommendations for 2024–2025 COVID-19 vaccination (3). CDC continues to monitor VE of 2024–2025 COVID-19 vaccines.

Acknowledgments

Allison Avrich Ciesla, Monica Dickerson, Amber Kautz, Josephine Mak, Abby L. Martin, Morgan Najdowski, Varsha Neelam, Lakshmi Panagiotakopoulos, Lauren Roper, Ralph D. Whitehead, Jr., CDC; Julio Angulo, Shanice L. Cummings, Claudia Guevara Pulido, Jennifer L. Luther, Rendie E. McHenry, Bryan P.M.M. Peterson, Neekar S. Rashid, Wanderson Rezende, Laura L. Short, Vanderbilt University Medical Center; William Fitzsimmons, Leigh Papalambros, University of Michigan.

Corresponding author: Ruth Link-Gelles, media@cdc.gov.

¹Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC; ²Westat, Rockville, Maryland; ³University of Colorado School of Medicine, Aurora, Colorado; ⁴HealthPartners Institute, Minneapolis, Minnesota; ⁵Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah; ⁶Kaiser Permanente Center for Health Research, Portland, Oregon; ⁷Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California; ⁸Indiana University School of Medicine, Indianapolis, Indiana; ⁹Regenstrief Institute Center for Biomedical Informatics, Indianapolis, Indiana; ¹⁰Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana; ¹¹Vanderbilt University Medical Center, Nashville, Tennessee; ¹²University of Michigan, Ann Arbor, Michigan; ¹³Intermountain Medical Center, Murray, Utah; ¹⁴University of Utah, Salt Lake City, Utah; ¹⁵University of Colorado School of Medicine, Aurora, Colorado; ¹⁶University of Iowa, Iowa City, Iowa; ¹⁷Wake Forest School of Medicine, Winston-Salem, North Carolina; ¹⁸Johns Hopkins University School of Medicine, Baltimore, Maryland; ¹⁹Hennepin County Medical Center, Minneapolis, Minnesota; ²⁰Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York; ²¹University of Washington, Seattle, Washington; ²²Baystate Medical Center, Springfield, Massachusetts; ²³Oregon Health and Sciences University, Portland, Oregon; ²⁴Emory University, Atlanta, Georgia; ²⁵Cleveland Clinic, Cleveland, Ohio; ²⁶Stanford University School of Medicine, Stanford, California; ²⁷University of California-Los Angeles, Los Angeles, California; ²⁸University of Miami, Miami, Florida; ²⁹Washington University, St. Louis, Missouri; ³⁰Baylor Scott & White Health, Dallas, Texas; ³¹Texas A&M University College of Medicine, Dallas, Texas; ³²Henry Ford Health, Detroit, Michigan; ³³Yale University School of Medicine, New Haven, Connecticut; ³⁴University of Arizona, Tucson, Arizona; ³⁵Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York; ³⁶New York-Presbyterian Hospital, New York, New York; ³⁷Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. James D. Chappell reports grants from Merck to study respiratory virus epidemiology among hospitalized children in Jordan. Natasha Halasa reports grants from Merck and participation on a CSL-Seqirus advisory board. Akram Khan reports grant or contract support from Dompe Pharmaceuticals, Direct Biologics, 4D Medical, and Vivacell Bio. Adam S. Lauring reports receipt of grant or contract support and consulting fees from Roche. Ithan D. Peltan reports institutional support from Novartis and Bluejay Diagnostics, and grant support from the National Institutes of Health. Ivana A. Vaughn reports institutional support from eMaxHealth, Eli Lilly, and Evidera PPD. Malini B. DeSilva reports institutional support from Westat, Inc. Stephanie A. Irving and Allison L. Naleway report institutional support from Westat for VISION funding. Michelle A. Barron reports payment or honorarium as a speaker bureau participant from Innoviva Specialty Therapeutics. Colin Rogerson reports receipt of an infrastructure grant from Indiana University Health to support the development of an Observational Medical Outcomes Partnership-based database at the Regenstrief Institute. Toan C. Ong reports receipt of consulting fees from Regenstrief Institute for serving as a domain expert in patient matching in global health informatics;

travel support from Patient-Centered Outcomes Research Institute (PCORI) to attend the 2023 PCORI annual meeting; and travel support from Regenstrief to attend the Open Health Information Exchange 23 meeting in Malawi. Nicola P. Klein reports institutional support from Sanofi Pasteur, Merck, Pfizer, Seqirus, and GSK; unpaid membership on an expert panel for a planned Hepatitis E Phase II vaccine clinical trial among pregnant women in Pakistan; unpaid membership on the Western States COVID-19 Scientific Safety Review Workgroup, Board on Population Health and Public Health Practice, National Academies of Science, Engineering, and Medicine, and the National Vaccine Advisory Committee Safety Subcommittee. Tamara Sheffield reports unpaid service as chair of the Utah Adult Immunization Coalition, membership on the CDC Advisory Committee on Immunization Practices Influenza Vaccine Work Group, and membership on the Utah Department of Health and Human Services Scientific Advisory Committee on Vaccines. Oussen Zerbo reports support from Moderna, Pfizer, and the National Institutes of Health to the Kaiser Foundation Research Institute for studies unrelated to the current work. No other potential conflicts of interest were disclosed.

CDC COVID-19 Vaccine Effectiveness Collaborators

Joshua Acidera, University of Washington/Harborview; Laura Aguilar Marquez, University of Colorado; Omobosola Akinsete, HealthPartners Institute; Harith Ali, Johns Hopkins University; Erika Alor, University of Colorado; Ike Appleton, University of Iowa; Julie Arndorfer, Intermountain Health; Olivia Arter, Washington University School of Medicine; Sarah W. Ball, Westat, Inc.; Jaskiran Bansal, Henry Ford Health; Anna Barrow, University of Colorado; Leonard Basobas, Stanford University; Adrienne Baughman, Vanderbilt University Medical Center; Paul W. Blair, Vanderbilt University Medical Center; Lawrence Block, Kaiser Permanente Northern California; Bryce Bosworth, University of Utah; Noah Brazer, Yale School of Medicine; Genesis Briceno, Oregon Health & Science University; Daniel Bride, Intermountain Health; Samuel M. Brown, Stanford University; Sydney Buehrig, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Ashley Bychkowski, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Sukantha Chandresakaran, University of California Los Angeles; Steven Y. Chang, University of California Los Angeles; Catia Chavez, University of Colorado School of Medicine; Dylan Clark, University of Washington/Harborview; Sydney A. Cornelison, Vanderbilt University Medical Center; Jonathan M. Davis, Westat, Inc.; Brian E. Dixon, Regenstrief Institute Center for Biomedical Informatics and Richard M Fairbanks School of Public Health; Thomas J. Duszynski, Regenstrief Institute Center for Biomedical Informatics and Richard M Fairbanks School of Public Health; Inih Essien, HealthPartners Institute; Yvette Evans, University of Colorado; William F. Fadel, Regenstrief Institute Center for Biomedical Informatics and Richard M Fairbanks School of Public Health; Cathy Fairfield, University of Iowa; Courtney Feitsam, University of Iowa; Samantha Ferguson, Stanford University; Tammy Fisher, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Omai Garner, University of California Los

Angeles; Sheila Gasparek, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Heath Gibbs, University of Iowa; Daniela Gonzalez, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Alexandra June Gordon, Stanford University; Anirudh Goyal, Yale School of Medicine; Carlos G. Grijalva, Vanderbilt University Medical Center; Sydney Guthrie-Baker, Stanford University; Jacob Hampton, University of Iowa; John Hansen, Kaiser Permanente Northern California; Ebaad Haq, Oregon Health & Science University; Adrian Hernandez-Frausto, Oregon Health & Science University; Kinsley Hubel, Oregon Health & Science University; Mariana Hurutado-Rodriguez, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Cameron Hypes, University of Arizona; Karen B. Jacobson, Kaiser Permanente Northern California; Milad Karami Jouzestani, Oregon Health & Science University; Sindhuja Koneru, Henry Ford Health; Padma Koppolu, Kaiser Permanente Center for Health Research; Olivia Krol, Oregon Health & Science University; Lily Lau, Stanford University; Jenna Lumpkin, Stanford University; Karen Lutrick, University of Arizona; Cara T. Lwin, Vanderbilt University Medical Center; Kevin Ma, CDC; Kimberly Manchester, Yale School of Medicine; Denisse Mariscal, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Amanda Martinez, University of Colorado; David Mayer, University of Colorado School of Medicine; Rylie McBride, University of Utah; David McDonald, Washington University School of Medicine; Maile McKeown, University of Washington/Harborview; Sachina Mensah, Washington University School of Medicine; Nicholas Mohr, University of Iowa; Paul Nassar, University of Iowa; Caroline O'Neil, Washington University School of Medicine; Josh Van Otterloo, Intermountain Health; Elianora Ovchian, Washington University School of Medicine; Bijal Parikh, Washington University School of Medicine; Jose Pena, Oregon Health & Science University; Cynthia Perez, Stanford University; Gabriela Perez, Baylor Scott & White Health, Baylor University Medical Center, Dallas; Vanessa Pitre, Stanford University; Edvinas Pocius, Oregon Health & Science University; Jacob Rademacher, University of Colorado; Mayur Ramesh, Henry Ford Health; Caitlin Ray, CDC and Goldbelt Professional Services LLC; Carolina Rivas, University of Miami; Safa Saeed, Johns Hopkins University; Akshay Saluja, Washington University School of Medicine; Elizabeth Salvagio Campbell, University of Arizona; Carleigh Samuels, Washington University School of Medicine; Maria Santana-Garces, Henry Ford Health; Tanisha Shack, Henry Ford Health; Samantha Simon, University of Colorado; Ine Sohn, Vanderbilt University Medical Center; Vasisht Srinivasan, University of Washington/Harborview; Hannah Strait, Wake Forest University; Amy Sullivan, University of Colorado; H. Keipp Talbot, Vanderbilt University Medical Center; Grace Kyin-ye Tam, Stanford University; Shruti Tirumala, Henry Ford Health; Cody Tran, University of California Los Angeles; Emily Tribbett, Oregon Health & Science University; Alyssa Valencia, Washington University School of Medicine; Ivan Valesquez, Yale School of Medicine; Lucy Vogt, Washington University School of Medicine; Kim Vu, Washington University School of Medicine; Francesca Yerbic, Washington University School of Medicine; Arda Yigitkanli, Yale School of Medicine; Anne Zepeski, University of Iowa.

References

1. Wiegand RE, Devine O, Wallace M, et al. Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: a conditional probability, causal inference, and multiplier-based approach. *Vaccine* 2025;49:126808. PMID:39889531 <https://doi.org/10.1016/j.vaccine.2025.126808>
2. Taylor CA, Patel K, Pham H, et al.; COVID-NET Surveillance Team. COVID-19–associated hospitalizations among U.S. adults aged ≥18 years—COVID-NET, 12 states, October 2023–April 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:869–75. PMID:39361542 <https://doi.org/10.15585/mmwr.mm7339a2>
3. Panagiotakopoulos L, Moulia DL, Godfrey M, et al. Use of COVID-19 vaccines for persons aged ≥6 months: recommendations of the Advisory Committee on Immunization Practices—United States, 2024–2025. *MMWR Morb Mortal Wkly Rep* 2024;73:819–24. PMID:39298394 <https://doi.org/10.15585/mmwr.mm7337e2>
4. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. *N Engl J Med* 2021;385:1355–71. PMID:34496194 <https://doi.org/10.1056/NEJMoa2110362>
5. DeCuir J, Surie D, Zhu Y, et al.; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. Effectiveness of original monovalent and bivalent COVID-19 vaccines against COVID-19–associated hospitalization and severe in-hospital outcomes among adults in the United States, September 2022–August 2023. *Influenza Other Respir Viruses* 2024;18:e70027. PMID:39496339 <https://doi.org/10.1111/irv.70027>
6. Payne AB, Ciesla AA, Rowley EAK, et al.; VISION Network. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. *Vaccine* 2023;41:7581–6. PMID:38000964 <https://doi.org/10.1016/j.vaccine.2023.11.025>
7. Lewis NM, Harker EJ, Leis A, et al. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses—IVY Network, September 1, 2022–March 30, 2023. *Vaccine* 2025;43:126492. PMID:39515195 <https://doi.org/10.1016/j.vaccine.2024.126492>
8. DeCuir J, Payne AB, Self WH, et al.; CDC COVID-19 Vaccine Effectiveness Collaborators. Interim effectiveness of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged ≥18 years—VISION and IVY Networks, September 2023–January 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:180–8. PMID:38421945 <https://doi.org/10.15585/mmwr.mm7308a5>
9. Wei J, Stoesser N, Matthews PC, et al. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. *Nat Commun* 2024;15:1008. PMID:38307854 <https://doi.org/10.1038/s41467-024-44973-1>